Detalhe da pesquisa
1.
De novo missense variants in RRAGC lead to a fatal mTORopathy of early childhood.
Genet Med
; 25(7): 100838, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37057673
2.
The long noncoding RNA TP73-AS1 promotes tumorigenicity of medulloblastoma cells.
Int J Cancer
; 145(12): 3402-3413, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31081944
3.
Effective and safe tumor inhibition using vinblastine in medulloblastoma.
Pediatr Blood Cancer
; 66(6): e27694, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30848061
4.
UBE2C promotes leptomeningeal dissemination and is a therapeutic target in brain metastatic disease.
Neurooncol Adv
; 5(1): vdad048, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37215954
5.
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
J Immunother Cancer
; 11(1)2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36639156
6.
Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer.
EMBO Mol Med
; 14(10): e15705, 2022 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35993110
7.
Primary cilia contribute to the aggressiveness of atypical teratoid/rhabdoid tumors.
Cell Death Dis
; 13(9): 806, 2022 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36127323
8.
The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors.
Nat Commun
; 13(1): 4061, 2022 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35831316
9.
The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma.
Cell Death Dis
; 12(10): 885, 2021 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34584066
10.
Different Calculation Strategies Are Congruent in Determining Chemotherapy Resistance of Brain Tumors In Vitro.
Cells
; 9(12)2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33333810
11.
A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells.
Mol Cancer Ther
; 19(8): 1736-1750, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32451331
12.
Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.
Oncotarget
; 8(7): 11460-11479, 2017 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28002790